differentiation. In the already described RUNX1/CBFA2T1 and RUNX1/CBFA2T3 fusion products, the transactivation domain of RUNX1 is replaced by almost the entire CBFA2T. The CBFA2T domains act in recruiting a co-repressor complex, composed of Nuclear hormone receptor CoRepressor (NCoR), mSin3A, Silencing Mediator of Retinoid and Thyroid hormone receptors (SMRT) and Histone DeACetylase (HDAC). As a result, RUNX1 target genes, normally activated by the wild-type RUNX1, are repressed. It has been recently shown that both wild-type CBFA2T and chimeric RUNX1/CBFA2T proteins show in vitro RNA-binding properties, suggesting novel scenarios in CBFA2T-mediated chromatin regulation. The high homology of the CBFA2T2 with respect to CBFA2T1 and CBFA2T3, strongly suggests that all the three chimeras resulting from their fusion with RUNX1 have a similar affect in leukemogenesis. In case 2, the two isoforms generated by the 5 0 RUNX1/3 0 C20orf112 retain the RUNX1 RHD domain, whereas the 5 0 C20orf112/RUNX13 0 transcript shows a ORF of 150 amino acids (data not shown), lacking the transactivation domain. We may speculate that C20orf112/RUNX1 chimera could bind to RUNX1 target genes, but are unable to regulate their transcription.
To the best of our knowledge, this is the first report in which RUNX1 chimeric genes resulting from rearrangements involving chromosomes 20 and 21 have been identified. It would be interesting to analyze additional AML cases showing t(20;21) to check their recurrence. In addition, according to our RQ-PCR results, both wild-type CBFA2T2 and C20orf112 are expressed at low levels in AML and normal BM, whereas the RUNX1/ C20orf112 and RUNX1/CBFA2T2 transcripts are expressed at higher levels than wild-type C20orf112 and CBFA2T2 genes in AML. This is probably because the expression of the fusion genes is driven, in both cases, by the RUNX1 promoter sequence.
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The authors declare no conflict of interest. Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) characterized by an excess of production of red blood cells driven by mutations in the Janus kinase 2 (JAK2) gene. 1 The most frequent mutation underlying PV is the JAK2 V617F mutation, found in approximately 95% of cases. Rare JAK2 V617F -negative cases have other mutations in JAK2. Recently, TET2 mutations have been found in approximately 15% of PV cases, 2,3 but a clear clinical or prognostic effect of those mutations has not been evidenced. 3 These additional molecular abnormalities can be detected in the founder clone of the disease, but may also be found in a JAK2 V617F -independent clone, or as secondary defects that could participate to the progression of the disease to a myelofibrotic or a blast phase. 4, 5 Interferon a-2a (IFNa) treatment has been shown to induce complete hematologic response, cytogenetic remission or reversion from monoclonal to polyclonal hematopoiesis in studies on few occasional PV patients. In a phase 2 trial of peg-IFNa, we observed a substantial decrease in JAK2 V617F allele burden in peripheral blood granulocytes from 29 patients treated with IFNa alone. 6 In 7 out of 29 patients (24%), JAK2 mutant alleles even became undetectable using an allelespecific PCR assay with a 1% sensitivity (baseline mutant JAK2 burden and time to complete molecular remission (CMR) are reported in Table 1 ). With these seven cases of CMRs, we were able to identify, by JAK2 V617F monitoring, the first homogeneous cohort of patients with measurable reduction of the PV clone. The study of this cohort may allow answering whether such CMR are associated with elimination of the PV clone.
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To test whether these JAK2 V617F CMRs found in circulating granulocytes were accompanied by the effective eradication of the malignant clone at the progenitor cell level, we performed erythroid progenitor cell cultures and JAK2 genotyping of individual colonies from five patients in CMR after 18 to 40 months of IFNa treatment. The five patients gave their informed consent for bone marrow (BM) aspiration and subsequent separation, culture and genotyping of progenitor cells, and this study was approved by the Institutional Review Board of the PVNord group. BM mononuclear cells were isolated after the ficoll hypaque gradient density separation procedure. Half of the cell suspension was seeded in culture dishes for our routine laboratory plasma clot assay in the presence or in the absence of 1 IU/ml recombinant erythropoietin (EPO) as previously described.
CD34
þ cells were isolated using an immunomagnetic procedure as described 7 from the remaining cell suspension. These CD34 þ cells were plated in standard methylcellulose assay (Stem Cell Technologies, Vancouver, Canada) supplemented with 20% fetal calf serum, 0.1% bovine serum albumine, stem cell factor (SCF), interleukin (IL)-3, in the presence or in the absence of 1 IU/ml EPO. Erythroid colonies were enumerated at day 7 (plasma clot assay) and day 12-14 (methylcellulose assay). Individual colonies grown from BM CD34 þ cells were harvested and screened for the JAK2 V617F mutation. At time of CMR plasma clot assays revealed the presence of few residual endogenous erythroid colonies (EECs) in the five patients, representing only 0.2 to 3.6% of the total of colonies grown with Epo. Methylcellulose assays (from BM CD34 þ cells) similarly showed few colonies in the absence of Epo in four patients (No. 1, 3, 4 and 5), representing 2.4-6% of colonies grown with Epo, while in one patient (No. 2) no colonies were detected (Table 1) . Thus, the hematological response and the disappearance of JAK2 V617F from peripheral blood granulocytes were accompanied by a dramatic reduction in the number of Epo-independent colonies in both plasma clot and methylcellulose progenitor culture assays.
Individual colonies obtained in the Epo methylcellulose culture of CD34 þ cells were picked for JAK2 V617F genotyping. Few JAK2 V617F -positive colonies were detected in the five patients (1.5-5.8% of the total harvested colonies) indicating that the PV clone was not eradicated (Table 1) . One patient (No. 1) had a total of three sequential BM aspirations after 18, 30 and 34 months of IFNa treatment. Plasma clot assays showed a continuous decrease in the ratio of EEC to the total number of colonies grown with Epo (from 1.1% to 0.4 and 0.2%), while the methylcellulose assays confirmed that only few colonies grew without Epo. In this patient, no residual JAK2 V617F -positive colonies were detected in a total of 114 colonies at month 34.
In all the four patients with colonies growing in the absence of Epo in methylcellulose, we surprisingly found a majority of JAK2 wild-type cells. In contrast to the plasma clot assay, the methylcellulose assay is performed in the presence of SCF and IL3, and we did not assess the phenotype of these cells. Thus, it may be possible that some of these colonies were not EECs, but rather non-erythroid cells that had undergone a few divisions during the 14-day culture in the presence of SCF and IL3.
Altogether these results indicate that PV patients who achieved CMR with INFa may still carry a small number of JAK2 V617F mutant progenitors able to form EECs. However, Abbreviations: BM, bone marrow; CMR, complete molecular remission; EEC, endogenous erythroid colony; EPO, erythropoietin; IFNa, interferon a-2a; MC, methylcellulose; SPC, standard plasma clot.
*Number (n1) of colonies per 250 000 BM mononuclear cells (mean of duplicates); **number (n1) of colonies per 1500 BM CD34+ cells (mean of two to six duplicate assays). þ cells. Each colored box area is proportional to the size of the clone as extrapolated from JAK2 and TET2 genotyping results. The acquired molecular events, the number of colonies that were analyzed for TET2 genotype, and the extrapolated percentage of each genotype (%) are indicated in the boxes. Sequence traces show the variety of genotypes that were found by the analysis of TET2 exon 11 and rs17253672 SNP in individual colonies. The asterisk points a colony with a heterozygous JAK2 V617F mutation, wild-type TET2 and a loss of heterozygosity assessed by TET2 rs17253672 sequencing. This colony could originate either from the TET2/JAK2 mutant clone (loss of the mutant allele of TET2, blue arrow) or from the JAK2 mutant clone (loss of one wild-type TET2 allele, red arrow).
analysis of serial samples from patient No. 1 shows that these progenitors dropped under the threshold of detection suggesting their exhaustion with longer IFNa treatment. In this regard, study of patients who stopped IFNa therapy after hematological and molecular response would be interesting. In our phase 2 study, IFNa treatment was withdrawn in 7 out of 35 evaluable patients because of sustained hematological response. Three of those patients also achieved CMR: two of them showed a molecular relapse after 6 months but were still in hematological complete remission (CR) without cytoreductive therapy after a median time of 20 months, and one was still in CMR after 35 months at last evaluation. Those results suggest that in selected cases IFNa can induce durable complete hematological and molecular responses even after treatment discontinuation. Long-term results of another IFNa study with JAK2 V617F monitoring are awaited to confirm those results in a larger number of patients. 8 Recent findings have underlined the existence of TET2 mutations that may precede JAK2 V617F in some MPN. 2, 3 We hypothesized that clones with such mutations may persist in spite of the eradication of the JAK2 V617F clone. Indeed, in this series of five patients who achieved complete JAK2 V617F CMR, we found in one patient (patient No. 3) a single-nucleotide deletion in exon 11 of TET2 leading to a frameshift and a premature stop codon (c.4577delC, p.Gln1526Serfs, named 'FS' further in the paper). Semi-quantitative estimation of the mutant TET2 indicated that 20-25% of the TET2 alleles (that is, 40-50% of the cells) were mutated in the diagnostic sample. Quantification of the mutant JAK2 found 20% of JAK2 V617F /total JAK2. To assess whether the TET2 mutant clone had dropped down in parallel with the JAK2 V617F clone during IFNa therapy, we sequenced TET2 exon 11 in the peripheral blood granulocytes at two different time-points of JAK2 V617F CMR (after 24 and 36 months of treatment). The proportion of mutant TET2 alleles remained unchanged in both follow-up samples ( Figure 1a) .
As TET2 mutations may occur in clones distinct from those bearing JAK2 V617F , 4,5 we sequenced TET2 exon 11 in JAK2 V617F -positive and -negative colonies grown from CD34 þ cells at the time of JAK2 V617F CMR (month 19) (Figure 1b) . Material was available for 12 JAK2 wild-type colonies and five JAK2 V617F mutant colonies. In all, 1 out of 5 JAK2 V617F colonies and 10 out of 12 JAK2 wild-type colonies harbored the TET2 mutation. One colony was homozygous for JAK2 V617F and TET2 wild-type, and one colony was JAK2 wild-type and homozygous for TET2 mutation, suggesting that mitotic recombinations or deletions had occurred on JAK2 and TET2 loci in separate clones, resulting in the loss of the wild-type alleles. To assess whether mutant JAK2 or mutant TET2 alleles could have been lost after mitotic recombination or deletion, we genotyped informative single-nucleotide polymorphisms (SNP) in each gene, one in exon 3 of TET2 (rs17253672, using direct sequencing), and one in intron 14 of JAK2 (rs12343867, using allele-specific competitive probe real-time PCR), in wild-type TET2 and wild-type JAK2 colonies, respectively. We found one JAK2 wildÀtype/V617F colony with a loss of heterozygosity at rs17253672 and wildtype TET2. We did not find any loss of heterozygosity of rs12343867 SNP in JAK2 wild-type/TET2 mutant cells. In contrast to the JAK2 V617F mutation, which has been shown to occur in separate clones from the same patient in at least 3% of cases, 9 the occurrence of the same TET2 mutation in two separate clones is unlikely. Thus, our results suggest that at the time of JAK2 V617F CMR two separate clones coexisted. The first clone initially acquired the JAK2 V617F mutation giving rise to JAK2 V617F /TET2 wild-type colonies. This clone then generated a subclone with the homozygous JAK2 V617F mutation, most likely through mitotic recombination. The second clone acquired the TET2 FS mutation and generated two subclones: one that lost the wild-type allele of TET2 by either mitotic recombination or deletion, and one that secondarily acquired the JAK2 V617F mutation, giving rise to JAK2 wildÀtype /TET2 FS and JAK2 wildÀtype/V617F /TET2 wildÀtype/FS colonies, respectively. We found a striking discrepancy in the frequency of TET2 mutant versus JAK2 mutant cells after IFNa therapy whereas both mutations had the same allelic burden before therapy. Indeed, 11 out of 17 (65%) colonies were found with a TET2 mutation in contrast to 7 out of 89 (5%) with a JAK2 mutation (Po0.001, Fisher's exact test), suggesting that IFNa targets JAK2 V617F mutant cells without affecting TET2 mutant cells. Alternatively, the discrepancy between JAK2 and TET2 molecular responses we observed could reflect different stem cell compartments carrying each mutation. If one considers that the TET2 mutation may be acquired in more immature stem cells than the JAK2 V617F mutation, exhausting those TET2 mutated cells could require longer exposition to IFNa than that necessary to eliminate JAK2 mutated cells.
In conclusion by the analysis of individual colonies grown from erythroid progenitors, we show that IFNa therapy led in all studied CMR patients to a dramatic decrease in the size of the JAK2 V617F clone. In one out of five patients, no JAK2 mutant colonies were ever detectable after 34 months of IFNa treatment. In contrast in one other patient with a biclonal TET2/JAK2 disease, IFNa therapy had a drastic effect on JAK2 V617F clones but did not affect the TET2 mutant clone. As this patient achieved hematologic and JAK2 molecular complete remissions on IFNa without reduction of the TET2 clone, we hypothesize that this treatment brought the patient back to a 'pre-proliferative' phase of his disease. Although this observation is made on a single patient with both TET2 and JAK2 mutations, it is in accordance with a model in which TET2 mutations are associated with the onset of a clinically undetectable pre-malignant clone giving rise to a myeloproliferative disease once it has acquired a second oncogenic mutation (that is, the JAK2 V617F in PV). A recent work identified a germline TET2 mutation in two siblings, one who presented at 49 years with PV after the acquisition of JAK2 V617F and the other with no hematopoietic disease. 5 Thus, the intrinsic effect of the TET2 mutations, when affecting one allele, may be very subtle regarding the aggressiveness of the clone. It has been previously shown that IFNa induced the reversion from clonal to polyclonal hematopoiesis in some patients. It can be envisioned that patients who bear a germline predisposition factor for PV would achieve polyclonal reversion under IFNa therapy, and that patients with acquired TET2 mutations (or other acquired genetic lesions) would rather revert to a pre-malignant mutant clonal hematopoiesis. To confirm the validity of our hypothesis of a different evolution between JAK2 and TET2 mutated clones during IFNa treatment it would be necessary to include a comprehensive molecular screening of MPN patients in future larger studies of IFNa therapy.
